Neuren Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $1.3B

Website

Clinical Trials

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

Phase 2

Withdrawn

Conditions: Prader-Willi Syndrome

Interventions: Drug: NNZ-2591

First Posted Date: 2023-05-30

Last Posted Date: 2024-12-09

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 20

Registration Number: NCT05879614

Locations: 🇺🇸
Rare Disease Research, Atlanta, Georgia, United States
🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸
Suburban Research, Media, Pennsylvania, United States

and more 1 locations

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)

Phase 2

Completed

Conditions: Phelan-McDermid Syndrome

Interventions: Drug: NNZ-2591

First Posted Date: 2021-08-27

Last Posted Date: 2024-11-25

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 18

Registration Number: NCT05025241

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

and more 1 locations

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)

Phase 2

Completed

Conditions: Pitt Hopkins Syndrome

Interventions: Drug: NNZ-2591

First Posted Date: 2021-08-27

Last Posted Date: 2024-08-09

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 16

Registration Number: NCT05025332

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 2 locations

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

Phase 2

Completed

Conditions: Angelman Syndrome

Interventions: Drug: NNZ-2591

First Posted Date: 2021-08-18

Last Posted Date: 2024-08-07

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 16

Registration Number: NCT05011851

Locations: 🇦🇺
Sydney Children's Hospital, Randwick, New South Wales, Australia
🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇦🇺
Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service, South Brisbane, Queensland, Australia

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: NNZ-2591
Drug: Placebo

First Posted Date: 2020-05-08

Last Posted Date: 2021-07-09

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 28

Registration Number: NCT04379869

Locations: 🇦🇺
Scientia Clinical Research, Sydney, New South Wales, Australia
🇦🇺
Linear Clinical Research, The Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

Phase 2

Completed

Conditions: Rett Syndrome

Interventions: Drug: NNZ-2566
Drug: Placebo

First Posted Date: 2016-03-22

Last Posted Date: 2020-08-14

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 82

Registration Number: NCT02715115

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 9 locations

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

Phase 2

Terminated

Conditions: Concussion

Interventions: Drug: NNZ-2566
Drug: Placebo

First Posted Date: 2014-03-31

Last Posted Date: 2018-02-05

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 32

Registration Number: NCT02100150

Locations: 🇺🇸
Fort Bragg, Fayetteville, North Carolina, United States

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

Phase 2

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: NNZ-2566
Drug: Placebo

First Posted Date: 2013-07-10

Last Posted Date: 2018-02-05

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 72

Registration Number: NCT01894958

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Nebraska, Omaha, Nebraska, United States
🇺🇸
UC Davis MIND Institute, Sacramento, California, United States

and more 14 locations

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Phase 2

Completed

Conditions: Rett Syndrome

Interventions: Drug: NNZ-2566
Drug: Placebo

First Posted Date: 2012-10-10

Last Posted Date: 2018-02-05

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 67

Registration Number: NCT01703533

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States
🇺🇸
Baylor School of Medicine, Houston, Texas, United States

Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration

Phase 1

Completed

Conditions: Brain Injuries, Traumatic

Interventions: Drug: NNZ-2566
Drug: Placebo

First Posted Date: 2011-08-19

Last Posted Date: 2012-11-22

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 24

Registration Number: NCT01420042

Locations: 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy